This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Bristol Myers (BMY) Announces CAR T Cell Therapy Breyanzi Data
by Zacks Equity Research
Bristol Myers' (BMY) CAR T cell therapy Breyanzi (lisocabtagene maraleucel) shows deep and durable responses in relapsed or refractory follicular lymphoma and mantle cell lymphoma.
Lilly's (LLY) Migraine Drug Fails Vis-a-Vis Pfizer's Nurtec ODT
by Zacks Equity Research
Results from a post-approval study show that treatment with Lilly's (LLY) Emgality failed to achieve statistical superiority over Pfizer's Nurtec ODT in preventing episodic migraine in adults.
Bristol Myers (BMY) Gets FDA Nod for Data Addition to Camzyos
by Zacks Equity Research
Bristol Myers (BMY) receives FDA approval for additional data to be added to the label of the heart drug Camzyos.
Roche (RHHBY) Gets FDA Approval for Blood Cancer Drug Columvi
by Zacks Equity Research
Roche's (RHHBY) blood cancer portfolio gets a boost with the approval of Columvi (glofitamab-gxbm) for treating patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
AbbVie's (ABBV) Skyrizi Meets Ulcerative Colitis Study Goals
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi achieves statistical significance with its primary endpoint of clinical remission in a late-stage study as a maintenance treatment for ulcerative colitis.
Journey Medical (DERM) Up on Rosacea Candidate's Positive Data
by Zacks Equity Research
Journey Medical's (DERM) phase I study, assessing the impact of DFD-29 on the microbial flora of healthy adults, obtains its primary endpoints.
Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data
by Zacks Equity Research
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) CAR T cell therapy has achieved an overall response rate of 83% in patients with Waldenstrom macroglobulinemia.
AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review
by Zacks Equity Research
The FDA grants priority review status to AstraZeneca's (AZN) capivasertib/Faslodex combination for the treatment of adult patients with HR-positive, HER2-negative locally advanced breast cancer.
Novartis (NVS) to Buy Chinook for $3.5B to Strengthen Pipeline
by Zacks Equity Research
Novartis (NVS) is looking to strengthen its renal pipeline with the acquisition of Chinook Therapeutics for $3.5 billion, which adds two late-stage medicines in development for rare, severe chronic kidney diseases.
Roche (RHHBY) Announces Positive Results From PNH Studies
by Zacks Equity Research
Roche (RHHBY) crovalimab achieves disease control in paroxysmal nocturnal hemoglobinuria patients in the phase III COMMODORE 1 and COMMODORE 2 studies.
AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies
by Zacks Equity Research
AstraZeneca (AZN) enters into a collaboration agreement with Quell Therapeutics to co-develop novel cell therapy options in major autoimmune indications for an upfront payment of $85 million.
Novartis (NVS) Sandoz Presents Standalone Growth Strategy
by Zacks Equity Research
Novartis generic arm, Sandoz, which will be spun off, expects strong growth as a standalone company, driven by increasing contribution from biosimilars.
FDA Accepts Vertex (VRTX), CRISPR's BLA Filings for Exa-Cel
by Zacks Equity Research
The FDA grants priority review to Vertex (VRTX)/CRISPR's (CRSP) filings for exa-cel in SCD, with a final decision expected in December.
Merck's (MRK) Keytruda for Liver Cancer to Undergo FDA Review
by Zacks Equity Research
FDA accepts Merck's (MRK) supplemental biologics license application for Keytruda plus chemotherapy for the treatment of patients with first-line advanced or metastatic biliary tract cancer.
Zacks.com featured highlights include Toll Brothers, Walmart, W.W. Grainger, Novartis and Graphic Packaging Holding
by Zacks Equity Research
Toll Brothers, Walmart, W.W. Grainger, Novartis and Graphic Packaging Holding are part of the Zacks Screen of the Week article.
FibroGen (FGEN) Pamrevlumab Fails DMD Study, Stock Down 8%
by Zacks Equity Research
FibroGen???s (FGEN) phase III study, evaluating pamrevlumab as a combination therapy in certain DMD patients, fails to meet its primary endpoint.
5 Dividend Growth Stocks to Buy for Outperformance
by Sweta Killa
Toll Brothers (TOL), Walmart (WMT), W.W. Grainger (GWW), Novartis (NVS) and Graphic Packaging (GPK) could be compelling picks for outperformance amid market volatility.
Intercept (ICPT) Announces Positive Data From PBC Study
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) announces new data showing the potential of a fixed-dose combination of OCA and bezafibrate to normalize multiple biomarkers in primary biliary cholangitis.
Merck (MRK) Sues US Government to Halt Drug Price Negotiations
by Zacks Equity Research
Merck (MRK) files a lawsuit against claiming that the federal government is violating the Constitution by forcing drugmakers to negotiate prices at below market rates.
Bausch (BHC) Down on Tentative Approval to Xifaxan ANDA
by Zacks Equity Research
Bausch (BHC) declines after the FDA grants tentative approval to Norwichs ANDA for a generic version of Xifaxan.
Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122
by Zacks Equity Research
Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for Parkinson's
Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Spreading
by Zacks Equity Research
Updated data from a mid-stage study showed that Moderna (MRNA)/Merck's personalized cancer vaccine combined with Keytruda reduces the skin cancer's spreading by 65% in melanoma patients.
Gilead (GILD), Arcus Announce Results From Mid-Stage NSCLC Study
by Zacks Equity Research
Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.
Novartis Announces Positive Data on Breast Cancer Drug Kisqali
by Zacks Equity Research
Novartis' (NVS) Kisqali reduces the risk of recurrence by 25% among patients with early breast cancer.